Navigation Links
Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation
Date:6/24/2009

St. Jude study shows personalized chemotherapy can improve cure rate and avoid the use of radiation in acute lymphoblastic leukemia treatment

MEMPHIS, Tenn., June 24 /PRNewswire-USNewswire/ -- Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS).

Despite radiation's success in treating ALL, it produces side effects that include second cancers, stunted growth, hormone imbalances and cognitive deficits. Optimized use of anticancer drugs, especially those instilled directly into the spinal fluid, have enabled clinicians to reduce radiation use, and only patients at highest risk for relapse have received cranial radiation.

Now, St. Jude researchers have established that radiation can be safely eliminated in all patients with the use of highly effective chemotherapy regimens. The findings appear in the June 25, 2009, issue of the New England Journal of Medicine.

"Cranial radiation was an invaluable treatment when it was introduced by St. Jude oncologists in the mid-1960s," said Ching-Hon Pui, M.D., chair of the St. Jude Department of Oncology and an American Cancer Society Professor. "It controlled CNS leukemia and boosted the cure rate for ALL from only 4 percent to 50 percent. But radiation's side effects led to the steady reduction of dosages and limited use to the highest-risk patients." According to Pui, the paper's lead author, about 20 percent of the approximately 3,400 cases of childhood ALL diagnosed in the U.S. each year are still treated with radiation. In some developing countries, radiation continues to be used in the majority of children with ALL.

"Ov
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...ANKLIN, Mass., Nov. 4 Ec...a diabetes management company developing the needl... wireless, transdermal continuous glucose monitori...em for transdermal drug delivery announced today t...ony(TM) Transdermal Continuous Glucose Monitoring ...
(Date:11/4/2009)...ISBANE, Calif., Nov. 4 I...at it has submitted an electronic New Drug Applica...ion (FDA) seeking approval to market pirfenidone f...nary fibrosis (IPF). Pirfenidone has been granted..., and also has been granted Orphan Drug status in ...
(Date:11/4/2009)...N FRANCISCO, Nov. 4 VIA ...ology company focused on the development of compou...lic disease, today announced that Dr. Rebecca Taub... will present "VIA-3196, a Liver-directed Thyroid ... in the Abstract Oral Session on Novel Biological ...
Breaking Medicine Technology:Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients 2Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients 3InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF 2InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF 3InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF 4VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 2VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 3VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 4Scientists identify specific markers that trigger aggressiveness of liver cancer 59827 1Scientists identify specific markers that trigger aggressiveness of liver cancer 59827 2Red Cross Implements Change to Enhance Donor Safety for Younger Donors 59824 1Red Cross Implements Change to Enhance Donor Safety for Younger Donors 59824 2New Study Details Complex Health Care Needs of Medicaids Highest Need Highest Cost Populations 59821 1New Study Details Complex Health Care Needs of Medicaids Highest Need Highest Cost Populations 59821 2New Study Details Complex Health Care Needs of Medicaids Highest Need Highest Cost Populations 59821 3
...alized Treatments -, PHILADELPHIA, Aug. 31 Resea... the risk of developing inflammatory,bowel disease...ed to identify the specific disease-causing,mutati...nes are,particularly strong candidates to be added... "As we continue to find genes that interact with ...
... 11- and 12-year-olds from,meningitis, whooping co...TLANTA, Aug 28 The Centers for Disease,Control an...ion and,Respiratory Diseases today announced that ...the parents of pre-teens are now available to broa...s, part of CDC,s Pre-Teen,Vaccine campaign, urge t...
Other Medicine Technology:New Genes Found for Inflammatory Bowel Disease in Children 2New Genes Found for Inflammatory Bowel Disease in Children 3New Genes Found for Inflammatory Bowel Disease in Children 4
(Date:11/4/2009)...e., Nov. 4 Online community member...regnant. During her ordeal, she discovered that th...hers in her same situation helped her to deal with...id become pregnant, she wanted to make sure and pr...ogging on to the My Community section of myRegenc...
(Date:11/4/2009)...nn., Nov. 4 The H1N1 st... to school nurses in Minnesota who are celebrating... Ceremonies scheduled for Friday, November 6th wil...made by school nurses to the health of children an...tional opportunity, planning committee members are...
(Date:11/4/2009)...Nov. 4 The United State... in a False Claims Act suit in the Western Distric...rsal Health Services Inc., Keystone Marion LLC and...stice Department announced today. They did busines...al facility in Marion, Va., that receives Medicaid...
(Date:11/4/2009)...n the heart-lung machine improved survival, study ...ews) -- Longer-term outcomes for people who had co...the use of a heart-lung machine, were worse than f...major study finds. , One year after surgery, ab...ure had died, suffered major complications, had he...
(Date:11/4/2009)...Nov. 4 Qualsec (OTC Bull...tly acquired VitaminSpice, LLC, announced that Dr ...apist and award winning reporter has agreed to be ...ke appearances, on behalf of VitaminSpice, on vari...ing Networks, News Talk Shows and satellite radio ...
Breaking Medicine News(10 mins):Health News:Regence's Social Media Web Site Gets a Facelift 2Health News:The Minnesota Nurses Association: School Nurses in Minnesota Celebrate 100 Years of Addressing Health Needs of School Children 2Health News:United States Intervenes in False Claims Act Suit Against Virginia Medicaid Providers 2Health News:Poorer Outcomes After 'Off-Pump' Bypass Surgery 2Health News:Poorer Outcomes After 'Off-Pump' Bypass Surgery 3Health News:Nationally Known Psychotherapist Dr. Robi Ludwig Joins Qualsec's Wholly-Owned Subsidiary VitaminSpice 2
...hese units of excellence no better, more costly, t...(HealthDay News) -- Having bariatric surgery at ho...t reduce a patient,s risk of complications or deat...e American College of Surgeons or the American Soc...
..., China, April 21 /PRNewswire-Asia-FirstCall/ -- T...I ), a manufacturer and supplier of,modernized tra..., China, today,announced that it has completed the...ns invite tenders from,various pharmaceutical manu...
...vate Telemedicine Company Maintains Quality During... 21 Specialists On Call, Inc., (SOC) a leading pr...s via telemedical link, has completed its 2009 Joi... clients, performing more than 4,000 consultations...
...AKE, N.J., April 21 /PRNewswire-FirstCall/ -- Pa...Par") today announced it has entered into a settle...("Reliant") that resolves patent litigation relate..., Par will have the right to introduce a generic v...
...vides Fiscal Year 2010 EPS Guidance in the Range o...orest Laboratories, Inc. (NYSE: FRX ), a U.S.-ba...arnings per share for the fourth quarter of fiscal...d $0.76. This compares to last year,s reported ea...
... "The Official Sponsor Of Birthdays(TM)" , , ATLA...ching a major brand revitalization effort focused ...tion and understand all it has to offer to defeat ...t the public has little understanding about all th...
Other Medicine News:Health News:Bariatric Surgery Centers Don't Deliver Better Outcomes 2Health News:Tianyin Pharmaceutical Co. Inc.'s Ginkgo Mihuan Oral Solution Completes 2009 Tenders 2Health News:Tianyin Pharmaceutical Co. Inc.'s Ginkgo Mihuan Oral Solution Completes 2009 Tenders 3Health News:Specialists On Call Renews Joint Commission Accreditation 2Health News:Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR 2Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 2Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 3Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 4Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 5Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 6Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 7Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 8Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 9Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 10Health News:Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation 11Health News:American Cancer Society Launches Major Brand Revitalization Effort to Help Broaden Consumer Understanding and Connections 2Health News:American Cancer Society Launches Major Brand Revitalization Effort to Help Broaden Consumer Understanding and Connections 3Health News:American Cancer Society Launches Major Brand Revitalization Effort to Help Broaden Consumer Understanding and Connections 4
BNP Assay for the ADVIA Centaur
...me ImmunoAssay (EIA) is as follows: a specific mon... well microtiter plate. After immunological reacti...lecule is covalently linked to the plate by glutar...uring treatment, Angiotensin II can react again wi...
RIDASCREEN Anti-RSV IgM Assay
ImmunoCard STAT!® RSV PLUS
Medicine Products: